Texas MPN Workshop 2021 | Clinical updates on the use of ropeginterferon for polycythemia vera
Richard Silver
• 4 Aug 2021
Richard Silver, MD, Weill Cornell Medical College, New York, NY, discusses the structure and use of ropeginterferon for the treatment of polycythemia vera, outlining its mechanism of action which allows for its administration every two to four weeks. Prof. Silver highlights the benefits of ropeginterferon therapy, and compares it to other interferon therapies which have also shown promise. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Richard Silver, MD, has participated in speakers’ bureau with PharmaEssentia and consultancy with AbbVie.
